In a previous study described in the accompanying paper (1), we investigated the effects of different densities of epithelial cells and macrophages on the barrier properties of the autologous alveolar cell co-culture model, and combined the model with the Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC; 2). The co-cultures were tested under submerged and air-liquid interface culture conditions. The barrier properties of the primary cell model were stable for several days under submerged conditions, but for less than 24 hours under air-liquid interface conditions. Macrophage clearance was also evident in the system. Although we were able to investigate potential cell toxicity safety concerns with a viability assay, it remains unclear whether safety issues that are not directly linked to cytotoxicity could be addressed with the autologous co-cultures under air-liquid interface conditions. The release of inflammatory markers is directly linked to macrophages in the human lung. We were interested in determining the scope of the immune responses generated -i.e. whether the model could be induced to show inflammatory and anti-inflammatory responses. The present publication, referred to as Part II, focuses on the applicability of the autologous co-culture model (which was thoroughly characterised in the accompanying paper, Part I; 1) as an in vitro inflammation system for testing the efficacy of anti-inflammatory stimulation. As proof-of-concept, we prepared a pulmonary dry powder formulation loaded with interleukin-10 (IL-10), which was used to treat the model.
Introduction
In a previous study described in the accompanying paper (1), we investigated the effects of different densities of epithelial cells and macrophages on the barrier properties of the autologous alveolar cell co-culture model, and combined the model with the Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC; 2). The co-cultures were tested under submerged and air-liquid interface culture conditions. The barrier properties of the primary cell model were stable for several days under submerged conditions, but for less than 24 hours under air-liquid interface conditions. Macrophage clearance was also evident in the system. Although we were able to investigate potential cell toxicity safety concerns with a viability assay, it remains unclear whether safety issues that are not directly linked to cytotoxicity could be addressed with the autologous co-cultures under air-liquid interface conditions. The release of inflammatory markers is directly linked to macrophages in the human lung. We were interested in determining the scope of the immune responses generated -i.e. whether the model could be induced to show inflammatory and anti-inflammatory responses. The present publication, referred to as Part II, focuses on the applicability of the autologous co-culture model (which was thoroughly characterised in the accompanying paper, Part I; 1) as an in vitro inflammation system for testing the efficacy of anti-inflammatory stimulation. As proof-of-concept, we prepared a pulmonary dry powder formulation loaded with interleukin-10 (IL-10), which was used to treat the model.
IL-10 is a potent anti-inflammatory cytokine that is a promising drug for the treatment of various inflammatory diseases (3) . The lung is severely affected by systemic and local inflammatory processes associated with medical conditions, such as mechanical trauma, haemorrhagic shock and endo-toxaemia (3, 4) . The resulting medical condition is known as acute respiratory distress syndrome (ARDS). The release of the pro-inflammatory cytokine interleukin-6 (IL-6), and tumour necrosis factor (TNF) in the case of endotoxaemia and haemorrhagic shock, was shown to play a pivotal role in the systemic inflammatory processes (4, 5) . Elevated plasma levels of these cytokines are associated with increased mortality rates and risk for the development of ARDS and multiple organ failure (4) . As a consequence, modulation of the excessive pro-inflammatory cytokine release was proposed as a promising therapeutic strategy (6) . It was shown that, following haemorrhagic shock, early treatment with the anti-inflammatory cytokine IL-10 can attenuate systemic and pulmonary inflammation (6, 7) . On the other hand, a strong systemic inhibition of inflammatory responses can cause an increase in the incidence of infection and sepsis (8, 9) .
In order to avoid these complications, a local pulmonary application of IL-10 was proposed by Kobbe et al. (10) . Mice previously subjected to haemorrhagic shock were treated with the pulmonary administration of nebulised recombinant murine IL-10. The local application decreased pulmonary inflammation, without affecting the systemic concentration of various pro-inflammatory cytokines or that of IL-10 (10). In another study on mice, pulmonary IL-10 treatment following bilateral femoral fractures, attenuated lung infiltration by neutrophils and decreased the expression of the intercellular adhesion molecule 1 (ICAM-1), without significant effects on the systemic inflammatory response (11) .
All the studies on the local pulmonary application of IL-10 involved the use of nebulised aqueous solutions of the cytokine. Such solutions suffer from the very limited stability of aqueous IL-10 solutions, so a promising alternative might be an IL-10 dry powder formulation. The requirements for such an aerosol powder formulation are: a) a significant fine particle fraction (FPF), to reach the target in the deep lung (alveolar macrophages); and b) biodegradable compounds to ensure safety and biocompatibility.
In order to translate the human in vivo situation into an in vitro concept with a stable dry powder formulation, and to demonstrate safety and efficacy, a relevant model of the human alveolus is needed. Co-culture systems mimic, in vitro, the cross-talk of cells and are able to address complex safety-related questions (12) . Therefore, we modified the set-up of the human autologous co-culture system described in our previous study (1) to establish a model of human lung inflammation. To avoid a reduction of a potential inflammatory response, the cells were grown without the usual addition of hydrocortisone to the epithelial culture medium. In the model, inflammation was induced with lipopolysaccharide (LPS). Spray-dried IL-10-loaded microparticles (IL-10 MPs) were prepared and characterised, with a main focus on their aerodynamic properties. Safety and efficacy were studied by aerosolisation and deposition of the particles with the PADDOCC on the cell culture model. Overall, the procedure represents a strategy to investigate aerosols for pharmaceutical applications, in a preclinical stage, without the use of animal experiments.
Materials and Methods

Materials
All the chemicals used were of analytical or higher grade. Bovine serum albumin (BSA; ≥ 96% purity), dimethylformamide (DMF), disodium phosphate heptahydrate, fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA), glacial acetic acid, L-leucine, 1N hydrochloric acid, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Sigmacote ® (SL2), sodium chloride, sodium dodecyl sulphate (SDS), 0.1N sodium hydroxide solution and trehalose dehydrate, were purchased from Sigma-Aldrich (St Louis, MO, USA). Recombinant human IL-10 (rhIL-10) and recombinant murine IL-4 (rmIL-4) with a purity of ≥ 98% were purchased from Peprotech (Rocky Hill, CT, USA). The murine mast cell line MC/9 was purchased from ATCC (Manassas, VA, USA). Transparent hard gelatin capsules (model ConiSnap ® ) of the standard size 3 (capsule volume 0.30ml) were obtained from Capsugel (Morristown, NJ, USA). For the pulmonary cell isolation, cell strainers of 100μm-pore size were used (BD, Franklin Lakes, NJ, USA). Trypsin and Percoll ® were purchased from Sigma-Aldrich. Epithelial cell adhesion molecule (EpCAM) antibody beads were obtained from Miltenyi Biotec (Bergisch-Gladbach, Germany). Snapwells were purchased from Corning (Schiphol-Rijk, The Netherlands). For the coating, fibronectin (BD, Heidelberg, Germany) and collagen (Sigma-Aldrich) were used (see Part I; 1). Small Airway Epithelial Cell Growth Medium (SAGM™) was obtained from Lonza (Verviers, Belgium), and lipopolysaccharide (LPS, from Escherichia coli) from Sigma-Aldrich. The Cytometric Bead Array (CBA) Flex Sets used for the determination of the concentrations of IL-6, IL-8, IL-10 and TNF in the cell culture medium were acquired from BD (Germany).
Preparation of IL-10-loaded microparticles
The spray-dried IL-10 MPs were formulated as follows. An aqueous solution with a concentration of 0.25% BSA, 0.23% trehalose and 0.05% leucine (all w/v) was prepared by dissolving the constituents in sterile, deionised filtered water. The pH was set to 7.4 by adding 0.1N NaOH. Subsequently, 0.25μg/ ml rhIL-10 was added. The solution was spraydried with a B-90 Nano Spray Dryer (Büchi Laboratoriums Technik AG, Flawil, Switzerland). Lee and co-workers thoroughly described the underlying physical and technical principles of the Nano Spray Dryer (13) . Briefly, the prepared solution was fed to the spray head by a peristaltic pump (Figure 1 ). In the spray head, the solution was dispersed into fine droplets via the vibration of a 4μm-sized mesh. The reservoir for the solution was ice-cooled to minimise heat-induced degradation of the IL-10. The inlet air temperature of the spray dryer was set to 50°C, and an air flow-rate of 140L/min was applied. The resulting outlet air temperature was in the range of 32-36°C. After this process, the dried particles were scraped off the collecting electrode with a plastic scraper. The collected particles were weighed and the yield was calculated based on the sprayed volume of the solution. Placebo (unloaded) particles were prepared in the same way, by using the excipient solution without the addition of IL-10.
Scanning electron microscopy
Images of the particles were obtained by scanning electron microscopy (SEM). The samples were mounted on carbon sticks, and sputter coated with a gold film of about 15nm thickness by using a Q150RES (Quorum Technologies Ltd, East Grinstead, UK). The SEM images were taken with an EVO HD15 (Carl Zeiss Microscopy GmbH, Jena, Germany).
In vitro aerosol deposition studies with the Next Generation Impactor
The aerodynamic properties of the spray-dried particles were determined by using fluorescencelabelled placebo particles. In the spray solution for these particles, in contrast to that for the unlabelled placebo particles, 20% of the BSA was substituted by FITC-BSA. Hard gelatin capsules of size 3 were filled with about 20mg of these particles and inserted into the chamber of a HandiHaler ® device (Boehringer Ingelheim, Ingelheim am Rhein, Germany; 14). The HandiHaler was coupled to the Next Generation Impactor (NGI; Copley Scientific, Nottingham, UK; 15). A solution of silicone oil in heptane (Sigmacote, SL2) was applied to coat the surfaces of the particle collection cups of the cascade impactor (16) . The preseparator of the NGI was filled with 10ml of 10mM PBS pH 7.4. A flow rate of 60L/min was applied for 4 seconds, to aerosolise the particles in the previously pierced capsule. After each run, the capsule chamber of the HandiHaler, the mouthpiece, the pre-separator and all stages of the NGI, were carefully rinsed with 10mM PBS pH 7.4 to dissolve the particles. The FITC-BSA concentrations were determined from the fluorescence intensity (excitation wavelength 490nm, emission wavelength 525nm), by using a microplate reader (Infinite M200; Tecan Group AG, Maennedorf, Switzerland). Each sample and each standard solution were measured in triplicate. The aerodynamic cutoff diameters for each stage (collection tube) of the NGI, and the micro-orifice collector for the applied flow rate of 60L/min, were taken from the publication by Marple et al. (17) , and the United States Pharmacopeia (18) . The mass median aerodynamic diameter (MMAD), the geometric standard deviation (GSD) and the FPF were determined as described in the United States Pharmacopeia (18).
Determination of particle-bound IL-10 bioactivity
The IL-10 bioactivity associated with the spraydried particles was determined by the ability of Evaluation of IL-10-loaded microparticles for the treatment of lung inflammation native IL-10 to induce the IL-4-dependent proliferation of murine MC/9 mast cells (19) , by using a colorimetric MTT assay (20) . Briefly, 10,000 cells in 200μl medium containing 5pg/ml murine IL-4 were added to each well of a 96-well microtitre plate, and treated for 48 hours with the IL-10 MP, which had been previously re-suspended in cell culture medium. For each sample, 10 wells were prepared. The human IL-10 standard was serially diluted with culture medium containing dissolved blank particles; for each standard concentration, four wells were prepared. A 20μl aliquot of 5mg/ml MTT in 10mM PBS pH 7.4 was added to each well, and the plates were incubated for 4 hours. Subsequently, the cells were lysed by adding 100μl of 20% (w/v) SDS dissolved in 47.8% DMF, 47.8% demineralised water, 2.0% glacial acetic acid and 2.5% 1N HCl (all v/v) to each well (20) . The plates were incubated overnight at 37°C. The absorbance at 570nm and 690nm was then measured by using a plate reader (Infinite M200). The absorbance measured at 690nm was subtracted from that at 570nm, to correct for cell debris. The IL-10 bioactivity associated with the particles was determined by relating the corrected mean absorbance values of the respective samples to those of the standards, the activity of which was defined as 100%.
Modelling lung inflammation treatment in vitro
The efficacy and safety of the IL-10 MP for pulmonary delivery was tested by using an alveolar coculture model based on primary human alveolar epithelial cells and macrophages. The design and properties of this model are described in detail in the accompanying paper (Part I; 1). The use of human tissue was approved by the local ethics committee (State Medical Board of Registration, Saarland, Germany). The co-cultures were used under air-liquid cell culture conditions with 100,000 macrophages/cm 2 and 300,000 epithelial cells/cm 2 on Snapwell™. For the present experiments, the protocol described in Part I (1) was slightly modified: after three days of culturing under submerged conditions, the epithelial cells were placed under airliquid conditions and further cultured in SAGM without hydrocortisone, to avoid an additional antiinflammatory stimulus ( Figure 2 ). We did not expect a meaningful transepithelial electrical resistance (TEER) in this set-up, as air-liquid conditions and the absence of hydrocortisone both have reducing effects on barrier properties. In order to initiate the inflammatory response, the co-culture was stimulated by the addition of 10μg/ml LPS (5μl per well, in balanced salt solution B [BSSB]) to the apical compartment of the cocultures immediately before particle deposition. The concentration of LPS was chosen according to the work of Fiorentino et al. (21) ; the volume of 5μl was used for practical reasons.
The amount and size of particles deposited in the PADDOCC was determined by applying fluorescently-labelled placebo particles to SEM carbon discs, in the absence of cells. The controlled deposition of the dry powder formulation was performed according to an established protocol (22) . Capsules of size 3 were filled with labelled particles and aerosolised in the PADDOCC onto SEM carbon discs. Their mean size and size distribution were investigated by correlative microscopy, combining fluorescence light microscopy (Axio Imager M1m, equipped with the LED system Colibri for excitation; Carl Zeiss Microscopy GmbH) and SEM (EVO HD15) (23) . The fluorescently-labelled placebo particles were deposited in the PADDOCC in empty Snapwells, to quantify the amount of particles. The Snapwells were rinsed with 10mM PBS buffer pH 7.4 to dissolve the particles and thus quantify them by determining the fluorescence intensity of the solution.
Finally, the co-cultures and the PADDOCC were combined to determine the safety and efficacy of spray-dried IL-10 MPs on primary human alveolar cells. Particles (IL-10-loaded or blank placebo particles) were deposited on the co-cultures. Overall, the number of cells isolated was sufficient for the investigation of five groups of samples in triplicate, in each case by using three independent cell isolations from three donors. For each donor, a new particle batch was produced. The five groups were denoted as: i) co-culture blank (unstimulated and untreated control); ii) IL-10 MPs (unstimulated and treated with IL-10 MPs); iii) LPS (LPS-stimulated and untreated); iv) LPS + IL-10 MPs (LPSstimulated and treated with IL-10 MPs); and v) LPS + unloaded MPs (LPS-stimulated and treated with blank microparticles). After the respective treatments, the cells were further incubated for 24 hours. The next day, after a 24-hour incubation period, samples from both the apical and basolateral compartments of the Snapwell inserts were taken, in order to quantify the cytokines present. Therefore, the cytokines were collected in BSSB (24) . A 500μl aliquot of BSSB supplemented with 0.1% BSA was added to the apical compartment and a 1000μl aliquot was added to the basolateral compartment, resulting in a final apical and basolateral volume of 500μl and 1500μl, respectively. These samples were frozen and stored at -80°C until they were analysed.
The cytokine concentrations were determined with a multiplexed, bead-based immunoassay (BD Cytometric Bead Array). In this immunoassay, fluorescently-labelled beads coated with monoclonal antibodies are used to simultaneously analyse the concentrations of multiple cytokines (25) . The samples were prepared according to the manufacturer's instruction, and were subsequently analysed with a FACSCalibur™ flow cytometer (BD), which permitted the determination of the concentrations of IL-6, IL-8, IL-10 and TNF in the same run.
Statistics
One-way analysis of variance (ANOVA) tests of the concentrations, in conjunction with the Tukey's range test, were performed by using Origin software (OriginPro2016G).
Results
Properties of the spray-dried IL-10 MP and deposition in the PADDOCC
The IL-10 MPs were spray-dried with a yield of 45% (SD 7%, n = 3). The bioactivity of IL-10 remaining after this process, as determined by means of MC/9 cell proliferation, amounted to 8% 
The white line indicates the direction of the particle flow. After release from the HandiHaler (A), the aerosol passes through the black tubes (B), and finally arrives in the deposition chamber (C). After three seconds, the revolver, containing three Snapwells (E), is changed from ventilation mode (D) to sedimentation mode (E), and the microparticles are deposited on the co-culture wells via sedimentation (D). The bottom diagram illustrates the coculture model: Macrophages and epithelial cells were co-cultured at the air-liquid interface from day 4. On day 5, the cells were stimulated with LPS and subsequently incubated with IL-10-loaded microparticles. Cytokine release was determined 24 hours after deposition of the microparticles (day 6).
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(SD 2%, n = 3) of the initial bioactivity. SEM images (Figure 3 ) of the spray-dried particles showed a rough and corrugated surface. As the spray-drying solution was dispersed via the vibration of a membrane with a pore size of only 4μm, small particles in the range of 0.2μm to 2μm were formed. The aerodynamic properties of the particles, as determined by means of the NGI, were as follows: the MMAD of the dispersed particles was 2.5μm and the GSD was 1.7μm. The FPF was 57%, which means that 57% of the particles had an aerodynamic diameter below 5μm. The aerodynamic key figures of the spray-dried particles are summarised in Table 1 , together with data characterising the aerosolisation process: 96% of the particles initially present within each capsule, were recovered in the inhaler and in the airway stages of the NGI (Figure 3 ). Of the recovered particles, 84% were deposited in the mouthpiece, the subsequent add-on parts and in the NGI. The rest remained within the HandiHaler. Particle deposition achieved by using the PADDOCC was determined in two different ways. First, the size of the particles deposited on the carbon discs was investigated by using correlative microscopy, as shown in Figure 4 . The figure shows an image obtained after deposition of FITC-BSA-loaded fluorescent particles on a blank SEM carbon disc in the PAD-DOCC. The labelled particles demonstrate a successful deposition. Second, the particles were deposited in empty Snapwell inserts, then dissolved in PBS and quantified. From three capsules, each containing 18mg of dry powder, 86μg/cm 2 (SD 21μg/cm 2 ) were detected in the Snapwell inserts, which is less than 1% of the initial amount in the capsules. 
Modelling lung inflammation treatment in vitro
In order to mimic lung inflammation and its medical treatment, the co-culture was stimulated by LPS and subsequently treated with IL-10 MPs, which were applied to the co-culture in the PAD-DOCC (Figure 2 ). The cytokine expression of the five groups of samples is shown in Figure 5 . The untreated control (co-culture blank) showed no release of TNF and only comparatively low levels of IL-6 and IL-8, reducing possible concerns about the M1 or M2 pre-activation of the macrophages as a consequence of the cell isolation procedure, the co-culture conditions, or the smoker donor status. Surprisingly, the treatment of unstimulated cells with IL-10 MP led to a noticeable secretion of IL-6 and IL-8. As expected, LPS stimulation resulted in a significant secretion of IL-6, IL-8 and TNF, demonstrating the successful modelling of lung inflammation. In the case of LPS-stimulated cocultures treated with IL-10 MPs (LPS + IL-10 MP), an IL-10 concentration of 804pg/ml (SD 162pg/ml) was evident in the apical compartment, whereas only marginal amounts of IL-10 (mean ≤ 6pg/ml) were detected in the untreated and placebo-treated cultures. The treatment of LPS-stimulated co-cultures with IL-10 MPs reduced IL-6 and TNF expression significantly. In contrast, IL-8 was not reduced, as compared with the untreated LPS control. Blank (placebo) particles had no anti-inflammatory effect on the stimulated co-culture (LPS + unloaded particles). On the contrary, they caused an increase in the concentrations of IL-6, TNF and IL-8. Overall, cytokines were mainly detected in the apical compartment of the co-culture. The Table 1 : Outcome of the in vitro aerosolisation of the FITC-BSA-loaded spray-dried microparticles by using the Next Generation Impactor
Recovery (%) Emitted dose (%) MMAD (μm) GSD (μm) FPF (%)
95.8 ± 6.5 83.8 ± 2.1 2.50 ± 0.05 1.71 ± 0.04 56.7 ± 11.8
The recovery, deposition (as the emitted dose), mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD) and fine particle fraction (FPF) of the FITC-BSA-loaded spray-dried microparticles are presented as the mean ± SD (n = 3).
standard deviation is due to donor-to-donor and well-to-well variation. The cytokine concentrations in the basolateral compartment were considerably lower, but showed similar tendencies.
Discussion
We evaluated the use of the human autologous coculture model as a tool to determine the efficacy of an anti-inflammatory inhalable IL-10-loaded dry powder formulation. In this study, the human autologous co-culture was successfully stimulated by LPS (Figure 5 ), resulting in a notable release of IL-6, TNF and IL-8, in comparison to TGF-β stimulation in a previous study (26) . No comparable secretion of IL-6, TNF or IL-8 was observed in the unstimulated control. This suggests that the cell isolation procedure, the air-liquid culture conditions and the co-culture of cells did not induce inflammatory or regulatory cellular activation. The strong inflammatory response observed reveals the applicability of the selected read-out marker for this model. Besides LPS, the deposition of IL-10 MPs on the unstimulated co-culture resulted in a measurable release of inflammatory markers. This might have been caused by mechanical stress induced by the application of particles, and could also explain the high level of IL-8. Tsuda et al. (27) described similar observations for IL-8 release after fibre-treatment of A549 cells. They concluded that the particle-cell interaction can evoke IL-8 responses, which can be more pronounced in non-static systems. Primary alveolar cells are even more sensitive to their environment than the A549 cell line. For example, Stucki et al. investigated the effects of mechanical stress on primary alveolar cells in a microfluidic system, and found that even the static culture showed increased IL-8 levels (28) . Another reason for the increase in IL-8 levels might be that the excipients used in the experimental formulations were not pyrogen-free; it cannot be excluded that excipient impurities caused this inflammatory effect. Both speculations are supported by the observation that the deposition of blank particles on the LPS-stimulated cells caused a further increase in the levels of the pro-inflammatory cytokines, as compared with the untreated LPSstimulated co-culture.
The treatment of the LPS-stimulated co-culture with IL-10 MPs significantly reduced the release of the inflammatory markers IL-6 and TNF, in comparison to the LPS-stimulated cells. These results demonstrate the power of the primary autologous co-culture to serve as a tool for the investigation of new anti-inflammatory drugs. In addition, it was shown that IL-10 might be applied as an antiinflammatory inhalable pulmonary dry powder formulation. In future experiments, steps could be taken to reduce the standard deviation: For example, replacing the primary cells with immortalised alveolar cells could eliminate donor-to-donor variation, and might lead to more-reproducible results (29) , and further optimisation of the PADDOCC could offer a more-controlled deposition of particles. In addition, LPS stimulation could be performed in the ALICE system (30) , to achieve a more standardised stimulus.
The preparation of such an aerosolisable dry powder formulation with particle sizes small enough to reach the deep lung (aerodynamic diameter below 5μm) was achieved by using the B-90 Nano Spray Dryer -the vibrating mesh technology permits the formation of very fine droplets, resulting in particles of suitable size for targeting the deep lung. The use of albumin is well-established and accepted in various drug delivery technologies intended for human application (31) . It has been shown that a high concentration of albumin is present in both bronchoalveolar lavage fluid (32) and exhaled endogenous particles (33) . Moreover, albumin is used as a stabiliser for solutions with low protein concentrations: it prevents surface adsorption of bioactive proteins through its nonspecific binding to surfaces itself. Further more, it facilitates pH-buffering of the spray-drying solution. Before the addition of IL-10, the pH of the excipient solution was adjusted to pH 7.4 with 0.1N NaOH, because the biological activity of IL-10 is irreversibly lost below pH 6 due to structural changes in the protein structure occurring under acidic conditions (34) . Trehalose is often used as an excipient for the spray-drying of proteins, because it effectively stabilises the protein during the drying process through a water replacement mechanism (35) . Leucine was added as an excipient, to enhance the aerodynamic properties of the particles. Spray-dried particles with leucine have a corrugated surface that reduces inter-particle adhesion and increases the respirable fraction of the powder (36) . The inlet temperature for the spray-drying process was set to a moderate temperature of 50°C, to reduce heat-induced degradation of IL-10. The outlet temperature during the spraydrying process ranged between 33°C and 35°C. Overall, the strategy was successful, resulting in a remarkable FPF of 57%. While the optimal particle size for deep lung deposition is still highly speculated, it has been frequently reported, as a rule of thumb, that particles in a range of approximately 1-5μm show an excellent deposition in the deep lung (37, 38) . Therefore, the NGI results indicate that the prepared spray-dried formulation is well suited for an effective delivery to the deep lung by using an established dry powder inhaler. However, the IL-10 bioactivity associated with the formulation was low (about 8%), but might be improved in future studies by optimising the spray-drying process and/or the excipient composition. increase in cellular expression of TNF and IL-8 was evident. This increase is a starting point for the investigation of the anti-inflammatory effects of drugs by using the model. Even if the amounts of cytokines released vary between different in vitro cell models, a standardised protocol and a comparison with primary cells might reveal that various cell models could successfully replace animal experiments, independent of the origin of the cells. Human primary autologous co-culture has several limitations with regard to its application to large screening experiments, namely, the monetary costs involved and the amount of cells that can be isolated. However, the methodology can be used to improve the understanding of cellular responses in the alveolar space and will aid the identification of differences between cell line-based models and primary models of the respiratory tract.
Conclusions
The inflammatory response in the human autologous co-culture model used in this study underlines the relevance of cell-based and tissue-based in vitro models of the respiratory tract. We were able to demonstrate how human primary cells from the same patient interact in the presence of inflammatory stimuli, and we were able to deposit particles (of a size relevant to the respiratory tract) directly on an air-liquid culture of alveolar cells. In addition, we investigated the therapeutic efficacy of a novel IL-10 formulation on human primary cells. With LPS stimulation, the model can serve as a powerful tool to identify new drugs for the treatment of pulmonary inflammatory diseases and to evaluate cell line-based models.
